Phocas Financial Corp. Supernus Pharmaceuticals, Inc. Transaction History
Phocas Financial Corp.
- $749 Billion
- Q4 2024
A detailed history of Phocas Financial Corp. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Phocas Financial Corp. holds 108,479 shares of SUPN stock, worth $3.47 Million. This represents 0.52% of its overall portfolio holdings.
Number of Shares
108,479
Previous 16,407
561.18%
Holding current value
$3.47 Million
Previous $593 Million
561.24%
% of portfolio
0.52%
Previous 0.44%
Shares
12 transactions
Others Institutions Holding SUPN
# of Institutions
303Shares Held
60.7MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$332 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$197 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$155 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$92.1 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$84.1 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.71B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...